Examine recurring software validation deficiencies across FDA warning letters and consent decrees, the organizational decisions behind them, and what regulators ultimately expect in remediation.
Includes live access & recording
Software validation observations continue to appear in FDA warning letters, inspection observations, and consent decrees across a wide range of regulated industries. While the specific technologies, systems, and business processes may differ, recurring patterns often emerge involving validation scope, change management, risk assessment, user requirements, testing rationale, electronic records, data integrity controls, and ongoing system oversight.
These observations frequently involve expectations associated with 21 CFR Part 11, 21 CFR Parts 210 and 211, and software validation principles described within FDA guidance documents. In many cases, the underlying issue extends beyond a missing document or incomplete protocol and reflects broader weaknesses in how organizations make and defend software validation decisions.
This session examines software validation observations through the lens of regulatory enforcement actions and remediation efforts — recurring compliance patterns, the organizational decisions that contributed to those outcomes, and the corrective actions regulators ultimately expected organizations to implement.
FDA warning letters and consent decrees often involve software systems that were already in routine use. The systems were supporting manufacturing, quality, laboratory, clinical, or business operations. Records were being generated. Data was being reviewed. Products were being released. Yet during inspections, regulators concluded that the validation evidence, risk controls, change management practices, or system oversight activities were insufficient to support continued reliance on those systems.
Organizations subject to Part 11 and GMP requirements often discover that enforcement actions focus less on the existence of validation documentation and more on whether validation decisions remained scientifically justified, risk-based, and sustainable over time. This session examines recurring patterns across warning letters and consent decrees and the practical lessons they offer for modern software validation programs.
By the end of this session, participants will be equipped to recognize and correct the validation weaknesses that drive real FDA enforcement outcomes.
Recognize recurring software validation deficiencies cited in FDA warning letters and consent decrees.
Identify validation decisions that commonly create long-term compliance exposure.
Address Part 11, data integrity, and electronic records issues behind major enforcement actions.
Identify risk assessment weaknesses frequently cited during FDA inspections.
Strengthen change management practices to avoid significant regulatory observations.
Anticipate FDA remediation expectations following major validation findings.
Prepare the evidence inspectors expect when software validation decisions are challenged.
Apply lessons learned from real enforcement actions under GMP and Part 11 requirements.
Focused areas that will strengthen how your organization defends software validation decisions before they attract regulatory attention.
See how the same validation weaknesses surface across warning letters and consent decrees, regardless of the specific technology or business process involved.
Understand the electronic records and data integrity issues that recur behind major software validation enforcement actions.
Identify the risk assessment and change management weaknesses inspectors most frequently cite.
Learn what FDA expects organizations to do — and to prove — once significant validation findings have been identified.
A comprehensive look at how software validation failures surface in FDA enforcement actions and what remediation ultimately requires.
Professionals across validation, quality, regulatory, and IT functions responsible for defending software validation decisions under FDA scrutiny.
Validation Professionals
Computer System Validation (CSV) Teams
Quality Assurance (QA) Departments
Quality Systems Personnel
Regulatory Affairs Departments
IT and Business System Owners
Compliance and Audit Professionals
Pharmaceutical, Biotechnology, and Medical Device Manufacturers
Software validation observations continue to appear in FDA warning letters, inspection observations, and consent decrees across a wide range of regulated industries. While the specific technologies, systems, and business processes may differ, recurring patterns often emerge involving validation scope, change management, risk assessment, user requirements, testing rationale, electronic records, data integrity controls, and ongoing system oversight — frequently tied to expectations under 21 CFR Part 11, 21 CFR Parts 210 and 211, and FDA software validation guidance.
FDA warning letters and consent decrees often involve software systems already in routine use — supporting manufacturing, quality, laboratory, clinical, or business operations, generating records, and releasing product — where regulators nonetheless concluded that validation evidence, risk controls, change management practices, or system oversight activities were insufficient to support continued reliance on those systems.
Enforcement actions tend to focus less on the existence of validation documentation and more on whether validation decisions remained scientifically justified, risk-based, and sustainable over time. Looking across warning letters and consent decrees reveals recurring patterns in how validation decisions break down, how weaknesses are discovered, and what FDA ultimately expects organizations to do when significant deficiencies are identified.
Meredith Crabtree has over 30 years' experience in regulated industries, ranging from Blood, Plasma, Tissue, Laboratory, Pharma, Medical Device, Cosmetics, Supplements, and Animal Health. This includes manufacturing, packaging, labelling and distribution operations.
Meredith is the owner of MLKC Consulting and is a Quality Consultant specializing in product label reviews, 3rd party inspections, Consent Decree and Recall support. She also performs regulatory assessments and Quality trainings.
Don't miss this essential training on the software validation patterns behind FDA warning letters and consent decrees. Secure your spot now.